Skip to main content
Signal8

REVELATION BIOSCIENCES, INC. (REVB) Form 10-Q — Nov 5, 2026

$REVBForm 10-QFiled Nov 5, 2026, 5:23 PM ET0001193125-26-450194Original filing

Revelation Biosciences reported a net loss of $9.6 million for the nine months ended September 30, 2026, up from $6.4 million a year ago, with cash of $9.1 million and an accumulated deficit of $59.1 million. Management stated that current cash will not sustain operations within one year, raising substantial doubt about the company's ability to continue as a going concern. A newly effective Nasdaq rule requires automatic delisting if the market value of listed securities stays below $5 million for 30 consecutive business days, and the company disclosed its market value is already below that threshold with no cure period.

Key figures

Total Assets
10022097
Cash Position
9121630
Shares Outstanding
683442
Q3 2026 net loss
$3,315,513
Net loss 9mo 2025
$6.4 million
Accumulated deficit
$59.1 million
Ga expense 9mo 2026
$5,330,134
Rd expense 9mo 2026
$4,808,183
Stockholders equity
$7.2 million
Warrants outstanding
1273796
Cumulative gross raised
$75.9 million net proceeds since inception
Net cash used in operating 9mo
$8.1 million
Total potentially dilutive securities
1316468

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.